RSS-Feed abonnieren
DOI: 10.1055/s-2008-1062699
© Georg Thieme Verlag KG Stuttgart · New York
Case Report: Excellent Response to Long-Term Higher Dose Single Olanzapine in a Case of Recurrent Brief Depression
Publikationsverlauf
received 20.08.2007
revised 28.12.2007
accepted 14.01.2008
Publikationsdatum:
23. Juli 2008 (online)
![](https://www.thieme-connect.de/media/pharmaco/200804/lookinside/thumbnails/10.1055-s-2008-1062699-1.jpg)
Abbreviations
ACTH
adrenocorticotropic hormone, corticotropin
BPD
borderline personality disorder
DIB
diagnostic interview for borderlines
DSM
Diagnostic and Statistical Manual of Mental Disorders
HDRS-17
Hamilton depression rating scale of 17 items
ICD
international classification of diseases
MD
major depression
OLZ
olanzapine
RBD
recurrent brief depression
SADS-L
the schedule for affective disorders and schizophrenia, lifetime version
T3
triiodothyronine
T4
tetraiodothyronine, thyroxine
TSH
thyroid-stimulating hormone
References
-
1
American Psychiatric Association
.
Diagnostic and statistical manual of mental disorders. 4th Edition . Washington, DC: American Psychiatric Association 1994 - 2 Angst J, Merinkangas K, Scheidegger P, Wicki W. Recurrent brief depression: a new subtype of affective disorder. J Affective Disorders. 1990; 19 87-98
- 3 Angst J, Sellaro R, Merikangas K. Depressive Spectrum Diagnoses. Comprehensive Psychiatry. 200; 41 39-47
- 4 Assion HJ, Jungck C. Off-label prescribing in a German psychiatric hospital. Pharmacopsychiatry. 2007; 40 30-36
-
5 Earley W, Mitchel M, Marquez E, Kurtz D, Falk D, Taylor CC, Cavazzoni P.
Preliminary pharmacokinetics and tolerability of higher dose olanzapine. Presented at the 157th annual meeting of the American Psychiatric Association . New York, NY May 1–6, 2004 - 6 Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry. 1978; 35 837-444
- 7 Glazer WM. Olanzapine and the new generation of antipsychotic agents: patterns of use. J Clin Psychiatr. 1997; 58 18-21
- 8 Gunderson JG, Kolb JE, Austin V. The diagnostic interview for borderline patients (DIB). Am J Psychiatr. 1981; 138 896-903
- 9 Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiology Drug Safety. 2003; 12 423-424
- 10 Jackson WC, Manning JS, Connor PD, Deardorff OG. Retrospective study of olanzapine in depressive and anxious states primary care. Primary care companion. J Clin Psychiatr. 2004; 6 199-202
- 11 Jarema M. Atypical antipsychotics in the treatment of mood disorders. Current Opinion in Psychiatry. 2007; 20 23-29
- 12 Karow A, Schnedler D, Naber D. What would the patient choose? Subjective comparison of atypical and typical neuroleptics. Pharmacopsychiatry. 2006; 39 47-51
- 13 Keck Jr PE, Strakowski SM, MacElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatr. 2000; 61 4-9
- 14 Nemeroff CB. Use of atypical antipsychotics in refractory depression and anxiety. J Clinical Psychiatr. 2006; 66 13-21
- 15 Pezawas L, Angst J, Kasper S. Recurrent brief depression revisited. Int Rev Psychiatry. 2005; 17 63-70
-
16 World Health Organization .
The ICD-10 Classification of Mental and BehaviouraI Disorders, Clinical Descriptions and Diagnostic Guidelines . WHO. Geneva 1992
Correspondence
J. M. De la FuenteMD, PhD
Lannemezan Psychiatric Hospital
Route de Toulouse
65300 Lannemezan
France
Telefon: +33/5/6299 55 25
Fax: +33/5/6299 53 05
eMail: jdlf@ch-lannemezan.fr